The GOOD Guide to Cannabis
Welcome to the golden age of marijuana. Indeed, the future is dope.
- Most Read
Server’s Facebook Post Tells The Scary Truth About The Restaurant Businessby Tod Perry
Woman Shares Texts Showing The Difference Between A Healthy And Controlling Relationshipby GOOD Staff
9 Nonthreatening Leadership Strategies For Womenby Sarah Cooper
Chilling Video Shows A Heroic Mom Fighting Off A Kidnapper In Broad Daylightby Tod Perry
The Best And Worst States To Have A Baby In 2018by Tod Perry
Servers Busted Making Fun Of Their Customersby Adam Albright-Hanna
Aretha Franklin's Shade Towards Taylor Swift Belongs In The Rock And Roll Hall Of Fameby GOOD Staff
Hilarious Girl Replaces Pictures Of Her Her Ex With Ryan Reynoldsby Tod Perry
Man Shares Beautiful Love Letter to ‘Hero’ Wife on Facebookby Craig Carilli
Even The Government Wants In On These Trailblazing Marijuana Research Programs
by Tosten Burks
Scientific momentum is so strong in the cannabis industry that even our straight-arrow federal government wants in. While the Drug Enforcement Administration still clings to the claim that the plant has no medical value, the National Institutes of Health funded 49 projects examining the therapeutic properties of cannabinoids last year. The NIH is also ramping up production at the University of Mississippi’s only federally funded marijuana farm, the exclusive supplier for Federal Drug Administration-approved studies. Here are some of the trailblazers to watch:
Multidisciplinary Association for Psychedelic Studies
The California-based nonprofit made history when it announced plans to study cannabis as a treatment for post-traumatic stress disorder in U.S. veterans. Its clinical trial investigating “smoked botanical marijuana” was the first to receive both FDA and DEA approval.
The British company’s natural cannabis-derived mouth spray, Nabiximols, was approved in the United Kingdom in 2010 to treat multiple sclerosis and is offered in 20 countries, excluding the United States. The company is now in late-stage clinical trials for a new cannabidiol-based drug to treat newborns with epilepsy.
University of Minnesota
The NIH gave the university its largest therapeutic cannabinoid-related grant last year—$1.8 million. The study will look at how compounds might prevent pain caused by sickle cell disease.
Scripps Research Institute
Neuroscientists at Scripps received $1.3 million from the NIH to investigate cannabidiol’s potential for treating alcoholism and drug addiction.
The California company is testing a cannabidiol-based drug, APD371, as a general analgesic. Early trials have showed success in treating osteoarthritic and neuropathic pain.